Yoshiyuki Hattori

Prof. Yoshiyuki Hattori

Department of Pharmaceutics, Hoshi University, 2-4-41, Ebara, Shinagawa-ku, Tokyo 142-8501, Japan
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2008 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AYAtsushi Yamada
Atsushi Yamada
YTYukimi Taniguchi
Yukimi Taniguchi
KKKumi Kawano
Kumi Kawano
THTakashi Honda
Takashi Honda
YHYoshiyuki Hattori
Yoshiyuki Hattori
YMYoshie Maitani
Yoshie Maitani
Purpose: Tumor cell targeting is a promising strategy for enhancing the therapeutic potential of chemotherapy agents. Polyethylene glycol (PEG)-coated (sterically stabilized) liposomes show enhanced accumulation on the surface of tumors, but steric hindrance by PEGylation reduces the association of the liposome-bound ligand with its receptor. To increase folate receptor (FR) targeting, we optimized the concentration and PEG spacer length of folate-PEG-lipid in liposomes. Experimental Design: Three types of folate-linked liposomal doxorubicin were designed and prepared by optimizing the concentration and PEG spacer length of folate-PEG-lipid in PEGylated or non-PEGylated liposomes and by masking folate-linked liposomes where the folate ligand is “masked” by adjacent PEG spacers. The liposome targeting efficacy was evaluated in vitro and in vivo. Results: In human oral carcinoma KB cells, which overexpress FR, modification with sufficiently long PEG spacer and a high concentration of folate ligand to non-PEGylated liposomes increased the FR-mediated association and cytotoxicity more than with PEGylated and masked folate-linked liposomes. On the contrary, in mice bearing murine lung carcinoma M109, modification with the folate ligand in PEGylated and masked folate-linked liposomes showed significantly higher antitumor effect than with non-PEGylated liposomes irrespective of the length of time in the circulation after intravenous injection. Conclusions: The results of this study will be beneficial for the design and preparation of ligand-targeting carriers for cancer treatment.

1 April 2004 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
TNTakahiro Nagamoto
Takahiro Nagamoto
YHYoshiyuki Hattori
Yoshiyuki Hattori
KTKozo Takayama
Kozo Takayama
YMYoshie Maitani
Yoshie Maitani

1 September 2007 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YMYoshie Maitani
Yoshie Maitani
SISaki Igarashi
Saki Igarashi
MSMamiko Sato
Mamiko Sato
YHYoshiyuki Hattori
Yoshiyuki Hattori

1 November 2008 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
TYTakashi Yoshizawa
Takashi Yoshizawa
YHYoshiyuki Hattori
Yoshiyuki Hattori
MHMotoki Hakoshima
Motoki Hakoshima
KKKimiko Koga
Kimiko Koga
YMYoshie Maitani
Yoshie Maitani


1 March 2005 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TSTomonori Shiokawa
Tomonori Shiokawa
YHYoshiyuki Hattori
Yoshiyuki Hattori
KKKumi Kawano
Kumi Kawano
YOYukino Ohguchi
Yukino Ohguchi
HKHiroko Kawakami
Hiroko Kawakami
YMYoshie Maitani
Yoshie Maitani
Purpose: To establish a novel formulation tumor-targeted drug carrier of lipophilic antitumor antibiotics, aclacinomycin A (ACM), folate-linked microemulsions were prepared and investigated both in vitro and in vivo.